Moderna’s (MRNA) leaked cancer-vaccine trial results looked “promising” on the surface, yet the biotech stock came under ...
Zacks Investment Research on MSN
MRNA tanks as positive phase III cancer therapy data fails to impress
Moderna MRNA, along with partner Merck MRK, reported detailed positive results from the phase III INTerpath-001 study ...
The addition of a personalized vaccine to standard adjuvant therapy reduced risk for recurrence or death by 42% among ...
Moderna’s (MRNA) cancer-vaccine rally hit a setback on Thursday as shares slid toward their worst week in three months and ...
Investors were awaiting full data from the late-stage trial of intismeran autogene plus Merck’s Keytruda at the European ...
A needle-free vaccination method protected mice against the viruses that cause COVID-19 and flu, offering a possible new way ...
Moderna (NasdaqGS:MRNA) has advanced its mRNA-based bird flu vaccine into a late-stage clinical trial, the first of its kind ...
LIBERTY is a Phase 3, randomized, double-blind clinical trial to evaluate the safety, serum virus neutralizing antibody responses, and pharmacokinetics of VYD2311, an mRNA COVID vaccine, and ...
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and ...
A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according ...
While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 ...
Moderna (MRNA) stock fell 18% to $202.63 after melanoma trial data leaked early. See key support levels and what to watch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results